$HMTXF Market Opening Value Hemostemix is a publicly traded biotechnology company listed on OTC. Today it has recorded a market opening price of $0.2151.
$HMTXF going up in flash on the OTC
$HMTXF today marked quite an impressive opening in the otc market and is currently trading with a steady pace at $0.1960 with a notable spike
Hemostemix hires new financial advisor to the family
Mr. Rick Groome who has effectively settled 2 securities firm, helping many successful biotechnology companies in providing funds over the last three decades has joined hemostemix as a special financial advisor.
Universal Ibogaine Inc. Market GraphUniversal Ibogaine Inc. holds a significant position over the OTC market with its greater difference between the lower and higher ranges of trading, which is $0.0258-$0.1143 in the last 52 weeks.
Potential aptitude of NCP-01 by Hemostemix Neuropathic pain synNeuropathic pain syndromes can be treated with NCP-01 and its autologous stem cell technology, which can treat disorders of the central and peripheral nervous systems. Spinal cord injury, chronic brainstem injury, traumatic brain injury, and peripheral nerve injury are all examples of traumatic injuries and many more
Uber- Technical AnalysisDisclaimer: I don’t own shares of UBER.
The below analysis is not a trading or investment recommendation & is only for learning purpose.
• Price is under the short term 20 period & long term 200 period moving averages.
• Price & RSI show an unconfirmed bullish divergence. Confirmation of this divergence is obtained through price closing above the
trendline & sustaining itself above the trend line.
• Immediate resistance points seems to be the 20MA, the intersection of price & the trendline shown in the chart, the most recent
pivot at $26.69 & the 200MA
• Immediate support is around $20.16 which is the most recent low.
• Price closing below $20.16 could trigger another round of downward movement.
• Volume increase has been seen around the recent lows made by price but the stock needs to see more of such high bouts of volume
to end the downward path & sustain it’s upward journey.
• An important development to look out for would be for the recurrence of hidden bearish divergence.
• The most recent hidden bearish divergence has been shown using dotted arrows on price & RSI.
• Hidden bearish divergence occurs when price continues to make new lower highs in a downtrend but RSI at the corresponding
price levels makes a higher high.
• Hidden bearish divergence is usually a trend continuation signal. Since the existing trend in this chart is downwards, hidden
bearish divergence tells us that the downward move hasn’t probably come to an end yet.
• Please exercise caution & always respect support & resistances for establishing stop losses while trading.
Good luck, make money!
Universal Ibogaine on a compassionate mission
UI is a life sciences industry on a mission to show the safety and efficacy of its ibogaine-based drug detox procedure in a planned Canadian Clinical Trial, with the goal of eventually licensing the protocol around the world.
Universal Ibogaine’s shares got approved for trading by Frankfur
Under the ticker symbol "JC4", UI's common shares have been registered for trade on the Frankfurt Stock Exchange, or Bourse Frankfurt. In Canada, UI will continue trading under the ticker name IBO on the TSX Venture Exchange and on the OTCQB under the ticker symbol IBOGF on the OTCQB
$IBOGF stock evaluation and analysis$IBO stock ticker to Universal Ibogaine a company that provides ibogaine addiction treatment to patients tormented from opioid addiction in Canada is currently trading swiftly at $0.03734 with an evident hike.
$IBOGF accord with blue digital media calls for added benefitsBlue Digital will be paid USD 27,000 for a three-month commitment beginning June 13, 2022. Additionally, Blue Digital will get 450,000 company's stock options to purchase common shares of the Company, with an exercise price of $0.10 per share, a three-year term, and one-third vesting at the conclusion of each month of service.
$IBOGF CEO Thoughts on H.C Wainwright.It gives UI great pleasure to announce that Nick Karos, CEO, will speak at the H.C. Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics and Beyond. On June 27, 2022, a hybrid online and offline event will take place. "H.C. Wainwright is a leader in the field and may be a significant strategic partner in our ongoing corporate finance roadmap," said Nick Karos, CEO of Universal Ibogaine. Another crucial step in raising awareness of our brand and service is the chance to share our story with this audience.
ROK has bottomed out!Stock printed a bullish candle last week with above average volumes right at the white trend line which is also 78.6% fib.retracement...
META has bottomed out!Stock has completed the 5 leg down move and has reached a strong support.........confluence of 88.6% fib.retracement, lower median of yellow pitchfork and white trend line,,,,,,,,,,,,,stock printed a bullish pinbar candle last week with above average volumes confirming buying interest..........looks like stock has bottomed out and worst is over for the stock..
$IBOGF- 30 day Average Volume
The volume of $IBOGF is increasing day by day. In the last 30 days the average volume of $IBOGF has been recorded to be $4.42K.
Universal Ibogaine in the Virtual Growth ConferenceUniversal Ibogaine Inc. is going to participate in the 2022 Virtual Growth Conference presented by Maxim Group LLC and hosted by M-Vest.
$IBOGF’s Addiction treatmentUniversal Ibogaine Inc. is a life science company with a mission to transform addiction treatment through the use of medicalized ibogaine and a global licensing model through a planned Canadian Clinical trial.
$IBOGF higher day rangeUniversal Ibogaine Inc. a life science company listed on OTC with the ticker symbol $IBOGF has been seen with a higher day range difference. The day range is $0.0367-$0.0385.
Addiction treatment by $IBOGF
Universal Ibogaine Inc. is a life science company with a mission to transform addiction treatment through the use of medicalized ibogaine and a global licensing model through a planned Canadian Clinical trial.
UI advantages of listing on the Frankfurt stock exchangeThe Frankfurt Stock Exchange (FSE) is Germany's largest stock exchange and the leading European destination for Canadian venture capital firms seeking exposure and liquidity in the European market. The FSE enables advanced electronic trading, settlement, and information technologies, allowing it to handle the increasing demands of cross-border trading.
The Universal Ibogaine Mission
Universal Ibogaine is working with Health Canada to undertake a planned clinical trial in Canada to demonstrate the safety and efficacy of the Ibogaine treatment protocol for opioid use disorder.
Universal Ibogaine on an empathetic mission
UI is a life sciences industry on a mission to show the safety and efficacy of its ibogaine-based drug detox procedure in a planned Canadian Clinical Trial, with the goal of eventually licensing the protocol around the world.
Blue digital media to effectively extend $IBOGF story
The UI story will be distributed through numerous platforms and audiences by Blue Digital. The expected outcome is increased knowledge of UI's plans to conduct research into the use of ibogaine as part of a continuum of care for opioid addiction and other addictions.
Dr. Sola, a co-founder of Universal Ibogaine and a member of its Board of Directors, has effectively administered over 3,700 ibogaine treatments, more than any other doctor in the world, at an independent clinic in Cancun, Mexico, where he is a partner.
Universal Ibogaine market cap growing relentlessly$IBOGF has established a remarkable market cap as compared to its fellow penny stocks in the market, currently the market cap is valued at $9.07 Million which has increased twice within a week.
